placebo in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results O’Donnell, 2021 (REV) 2.13 [0.95; 4.78]
PlasmAr, 2020 (REV) 1.08 [0.54; 2.14]
1.46 [0.75 ; 2.84 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 37% 556 low not evaluable deathsdetailed results O’Donnell, 2021 (REV) 2.13 [0.95; 4.78]
PlasmAr, 2020 (REV) 1.08 [0.54; 2.14]
1.46 [0.75 ; 2.84 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 37% 557 low not evaluable deaths (time to event analysis only)detailed results PlasmAr, 2020 (REV) 1.08 [0.54; 2.14]
1.08 [0.54 ; 2.14 ] PlasmAr, 2020 (REV) 1 0% 334 NA not evaluable clinical improvementdetailed results O’Donnell, 2021 (REV) 0.83 [0.61; 1.14]
PlasmAr, 2020 (REV) 1.23 [0.76; 2.00]
0.97 [0.67 ; 1.41 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 44% 556 low not evaluable clinical improvement (28-day)detailed results O’Donnell, 2021 (REV) 0.72 [0.38; 1.37]
0.72 [0.38 ; 1.37 ] O’Donnell, 2021 (REV) 1 0% 223 NA not evaluable clinical improvement (time to event analysis only)detailed results O’Donnell, 2021 (REV) 0.83 [0.61; 1.14]
PlasmAr, 2020 (REV) 1.00 [0.76; 1.32]
0.92 [0.75 ; 1.14 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 0% 557 low not evaluable mechanical ventilationdetailed results O’Donnell, 2021 (REV) 0.67 [0.21; 2.14]
PlasmAr, 2020 (REV) 1.16 [0.52; 2.59]
0.97 [0.50 ; 1.88 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 0% 556 low not evaluable serious adverse eventsdetailed results O’Donnell, 2021 (REV) 1.57 [0.86; 2.86]
PlasmAr, 2020 (REV) 0.71 [0.40; 1.28]
1.05 [0.49 ; 2.27 ] O’Donnell, 2021 (REV), PlasmAr, 2020 (REV) 2 70% 552 low not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 23:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
